Study on the Effects of Oxycodone on Postoperative Analgesia and Immune Function in Tuberculosis Patients Undergoing Thoracoscopic Surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500115473

Enrollment

Unknown

Registered

2025-12-26

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Oliceridine Group:Postoperative analgesia was administered using the novel opioid "oliceridine".

Sufentanil group:Postoperative analgesia was administered using the conventional opioid sufentanil.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with active tuberculosis according to industry-standard diagnostic criteria, scheduled for elective thoracoscopic surgery (e.g., wedge resection, segmentectomy, lobectomy, pleural surgery, etc.). 2.No severe malnutrition (serum albumin >=30 g/L) or metabolic disorder (fasting blood glucose<=11.1 mmol/L). 3. American Society of Anesthesiologists (ASA) Physical Status Classification of I-III. Aged 18-80 years, regardless of gender. 4.Informed of the study's content and objectives, voluntarily agree to participate, and sign the informed consent form..

Exclusion criteria

Exclusion criteria: 1. Severe cardiopulmonary dysfunction; 1.or hepatic/renal insufficiency (Child-Pugh Class C, estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73m^2). 2. Long-term use of immunosuppressants, or concurrent other immune-related diseases such as HIV infection, active viral hepatitis, or autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, etc.). 3. Acute disseminated tuberculosis (e.g., miliary tuberculosis, tuberculous meningitis) occurring within 1 month prior to surgery. 4. Known allergy or contraindication to opioid medications (e.g., sufentanil, oxycodone). 5. Pregnancy or lactation. 6. Participation in any other clinical trial within 1 month prior to surgery. 7. Cognitive or language impairment that would impede cooperation with pain assessment. 8. History of drug or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale Score;	—

Secondary

Measure	Time frame
Percentage of CD8+ (cells);Incidence of pulmonary complications within 7 days after surgery;CD4+/CD8+ ratio;Adverse reaction;IFN-?;Percentage of CD4+ (cells);TNF-a;IL-6;Percentage of CD3+ (cells);Percentage of NK (cells);IL-10;	—

Countries

China

Contacts

Public ContactZhao Zijun

Hebei Provincial Chest Hospital

86231721@qq.com+86 311 8691 1232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026